Interventional study descriptive statistics.
(Tab 1) Characteristics of patients compared in the patients in the interventional study 15 Participants who met the inclusion criteria were assigned to intervention with nanocrystallized fenofibrate (TriCor, AbbVie Inc, North Chicago, IL USA) at a dose of 145 mg (1 tablet) once per day. Standard care for severe-hospitalize COVID-19 patients was provided according to local practice: antiviral treatment, vitamin D3, low-dose glucocorticoids, convalescent plasma, and supportive care as well as antipyretic for symptoms of fever (products containing paracetamol, or non-steroidal anti-inflammatories such as aspirin and ibuprofen) and dextromethorphan for symptoms of cough. Standard chronic treatments were continued unless COVID-19, clinical status, or fenofibrate treatment was a counterindication for the treatment. Control patients were collected from the observational study’s database and filtered to patients that meet the inclusion criteria, were admitted with low immunoinflammatory stress (NLR <10 at admission), and were treated according to the standard care used in the interventional study. SBP, systolic blood pressure; DBP, diastolic blood pressure; COPD, chronic obstructive pulmonary disease; SpO2, oxygen saturation; ECMO, extracorporeal membrane oxygenation; IQR, interquartile range. Continuous variables were expressed as median [IQR] and were compared with a Mann-Whitney U test. Categorical variables were expressed as a count and percentage (%) and compared with a chi-squared test or Fisher’s exact test. The sample size is detailed in each display item. (Tab 2) Cox regression model of 28-days mortality in the treatment group versus control. Adjusted HR and p-values were calculated based using an unadjusted Cox regression model, a Cox regression model adjusting for age, gender, and pre-existing comorbidities (smoking, asthma, COPD, DM, hypertension, diabetes, coronary heart disease, obesity, dyslipidemia, cerebrovascular disease, chronic liver disease, and chronic kidney disease) or a Cox regression model adjusting for significantly different patient characteristics, obesity, chronic kidney disease, and SpO2. (A) Cox regression model of 28 days hospital discharge. (B) Cox regression model of 28 days oxygen withdrawal. (C) Cox regression model of 28 days mortality. There were no deaths recorded in the treatment patients, resulting in monotone likelihood (non-convergence of likelihood function, Firth’s penalized maximum likelihood bias reduction method was implemented to calculate hazard ratios and confidence intervals).